Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Lowered to $485.00 at Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has reduced its price target for Vertex Pharmaceuticals from $535.00 to $485.00, maintaining an "overweight" rating on the stock.
• Other analysts have also downgraded their ratings and price targets for Vertex, with a consensus rating of "Moderate Buy" and an average target price of $500.32.
• Vertex Pharmaceuticals currently has a market capitalization of $121.28 billion and reported a quarterly revenue of $2.94 billion, reflecting an 11.3% increase compared to the previous year.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) had its price target decreased by equities researchers at Cantor Fitzgerald from $535.00 to $485.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has an "overweight" rating on the pharmaceutical company's stock. Cantor Fitzgerald's price target would indicate a potential upside of 25.76% from the stock's previous close. Cantor Fitzgerald also issued estimates for Vertex Pharmaceuticals' FY2026 earnings at $18.33 EPS.

Several other research analysts also recently issued reports on VRTX. JPMorgan Chase & Co. upped their price objective on Vertex Pharmaceuticals from $515.00 to $517.00 and gave the stock an "overweight" rating in a report on Monday, July 14th. HC Wainwright cut their price target on Vertex Pharmaceuticals from $550.00 to $478.00 and set a "buy" rating on the stock in a research note on Tuesday. Leerink Partnrs cut Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 6th. Royal Bank Of Canada set a $420.00 price objective on Vertex Pharmaceuticals and gave the stock a "sector perform" rating in a research report on Tuesday, June 17th. Finally, Stifel Nicolaus cut their target price on shares of Vertex Pharmaceuticals from $494.00 to $455.00 and set a "hold" rating on the stock in a research report on Tuesday. Thirteen analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $497.10.

Vertex Pharmaceuticals Stock Up 2.8%

Vertex Pharmaceuticals stock traded up $10.67 during mid-day trading on Tuesday, hitting $385.65. The company's stock had a trading volume of 4,725,510 shares, compared to its average volume of 1,652,404. The company has a market cap of $99.03 billion, a PE ratio of 27.57 and a beta of 0.44. Vertex Pharmaceuticals has a 52-week low of $372.35 and a 52-week high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.52 and a quick ratio of 2.29. The firm's 50 day moving average is $453.73 and its 200 day moving average is $466.25.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, topping the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%. The business had revenue of $2.94 billion during the quarter, compared to analysts' expectations of $2.90 billion. During the same quarter in the previous year, the firm earned ($12.83) EPS. The firm's revenue was up 11.3% compared to the same quarter last year. On average, analysts anticipate that Vertex Pharmaceuticals will post 15.63 earnings per share for the current year.

Institutional Trading of Vertex Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Brighton Jones LLC increased its stake in shares of Vertex Pharmaceuticals by 15.0% during the fourth quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company's stock valued at $1,783,000 after buying an additional 579 shares during the period. Arrowstreet Capital Limited Partnership purchased a new position in shares of Vertex Pharmaceuticals in the 4th quarter valued at approximately $3,731,000. Polymer Capital Management US LLC purchased a new stake in shares of Vertex Pharmaceuticals during the fourth quarter valued at $329,000. Bank of Montreal Can lifted its holdings in shares of Vertex Pharmaceuticals by 4.3% during the fourth quarter. Bank of Montreal Can now owns 581,181 shares of the pharmaceutical company's stock worth $234,042,000 after purchasing an additional 23,964 shares during the period. Finally, Shelton Capital Management increased its stake in shares of Vertex Pharmaceuticals by 1.2% in the fourth quarter. Shelton Capital Management now owns 54,631 shares of the pharmaceutical company's stock worth $22,000,000 after acquiring an additional 647 shares during the period. Institutional investors own 90.96% of the company's stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.